Author:
Ranchon Florence,Salles Gilles,Späth Hans-Martin,Schwiertz Vérane,Vantard Nicolas,Parat Stéphanie,Broussais Florence,You Benoît,Tartas Sophie,Souquet Pierre Jean,Dussart Claude,Falandry Claire,Henin Emilie,Freyer Gilles,Rioufol Catherine
Abstract
Abstract
Background
In spite of increasing efforts to enhance patient safety, medication errors in hospitalised patients are still relatively common, but with potentially severe consequences. This study aimed to assess antineoplastic medication errors in both affected patients and intercepted cases in terms of frequency, severity for patients, and costs.
Methods
A 1-year prospective study was conducted in order to identify the medication errors that occurred during chemotherapy treatment of cancer patients at a French university hospital. The severity and potential consequences of intercepted errors were independently assessed by two physicians. A cost analysis was performed using a simulation of potential hospital stays, with estimations based on the costs of diagnosis-related groups.
Results
Among the 6, 607 antineoplastic prescriptions, 341 (5.2%) contained at least one error, corresponding to a total of 449 medication errors. However, most errors (n = 436) were intercepted before medication was administered to the patients. Prescription errors represented 91% of errors, followed by pharmaceutical (8%) and administration errors (1%). According to an independent estimation, 13.4% of avoided errors would have resulted in temporary injury and 2.6% in permanent damage, while 2.6% would have compromised the vital prognosis of the patient, with four to eight deaths thus being avoided. Overall, 13 medication errors reached the patient without causing damage, although two patients required enhanced monitoring. If the intercepted errors had not been discovered, they would have resulted in 216 additional days of hospitalisation and cost an estimated annual total of 92, 907€, comprising 69, 248€ (74%) in hospital stays and 23, 658€ (26%) in additional drugs.
Conclusion
Our findings point to the very small number of chemotherapy errors that actually reach patients, although problems in the chemotherapy ordering process are frequent, with the potential for being dangerous and costly.
Publisher
Springer Science and Business Media LLC
Subject
Cancer Research,Genetics,Oncology
Reference33 articles.
1. Kohn LT, Corrigan JM, Donaldson MS: To err is human: Building a safer health system. 1999, Washington DC: National Academy Press
2. Brennan TA, Leape LL, Laird NM, Hebert L, Localio AR, Lawthers AG, Newhouse JP, Weiler PC, Hiatt HH: Incidence of adverse events and negligence in hospitalized patients. Results of the Harvard Medical Practice Study I. N Engl J Med. 1991, 324: 370-376. 10.1056/NEJM199102073240604.
3. National coordinating council on medication error reporting and prevention. [http://www.nccmerp.org/aboutMedErrors.html]
4. Phillips J, Beam S, Brinker A, Holquist C, Honig P, Lee LY, Pamer C: Retrospective analysis of mortalities associated with medication error. Am J Health Syst Pharm. 2001, 58: 1835-1834.
5. Klys M, Konopka T, Scislowski M, Kowalski P: Fatality involving vinblastine overdose as a result of a complex medical error. Cancer Chemother Pharmacol. 2007, 59: 89-95.
Cited by
89 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献